Business Wire

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and ...

BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced ...
EurekAlert!

Structure-based development of potent and selective type-II kinase inhibitors of RIPK1

This new article publication from Acta Pharmaceutica Sinica B, discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting ...
GEN

Quantitative Kinase Target Engagement

Kinases constitute a family of more than 500 enzymes and play critical roles in cellular signaling, both in normal and diseased cells. As a result, kinases continue to be key drug targets, especially ...
ascopubs.org

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial ...
Business Wire

Ajax Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), ...
Nasdaq

Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic

– Financing led by Goldman Sachs Alternatives with participation by new investors Lilly, Vivo Capital, RA Capital Management, Point72 and existing investors – – AJ1-11095 will be the first Type II ...